Abstract
Objectives To determine if interventions aimed at air travellers can delay establishment of a SARS-CoV-2 outbreak in a previously unaffected country.
Design Simulation study
Setting Countries with no sustained SARS-CoV-2 transmission and with no shared border with affected regions
Participants Infected air travellers
Interventions Syndromic screening at departure and/or arrival & traveller sensitisation to the COVID-2019-like symptoms with the aim to trigger rapid self-isolation and reporting on symptom onset.
Main outcome measures The achievable delay until a major local outbreak is likely to occur
Results We evaluated traveller sensitisation effectiveness in reducing the number of secondary cases of 30, 50 and 70%, and assumed either 1, 10, or 100 infected travellers per week. Early in the outbreak when only few infected travellers arrive, traveller sensitisation can delay a major outbreak in a previously unaffected region. For 50% sensitisation effectiveness, and assuming 1 infected traveller per week, we find that in 75% of simulations the outbreak is delayed by at least 11 days (97.5% of simulations: at least 7 days). The possible delay decreases rapidly for more travellers, lower effectiveness of sensitisation, higher R0 or lower heterogeneity thereof. Syndromic traveller screening at departure and/or arrival can further enhance outbreak delays. In combination with sensitisation, syndromic screening can delay an outbreak substantially longer. In 75% of simulations we find an outbreak delay of at least 111 days (97.5% of simulations: at least 23 days) for 1 infected traveller per week and at least 9 days (97.5% of simulations: at least 4 days) for 10 infected travellers per week.
Conclusion Air-traveller targeted interventions, particularly in combination, can delay local SARS-CoV-2 outbreaks in the magnitude of a few weeks to potentially even months if the number of infected travellers remains low.
Aim To determine if interventions aimed at air travellers can delay establishment of a SARS-CoV-2 outbreak in a previously unaffected country with no shared border with China.
Methods Summary Determining how many imported cases are needed to trigger an outbreak in a new location is critical to quantifying if SARS-CoV-2 outbreaks can be delayed. Here we rely on the “outbreak threshold”, which is a function of the average number of secondary cases produced by each infected case, plus the variation from person-to-person in how many secondary cases they generate (often referred to as “the dispersion parameter, k”). We define a traveller intervention as either: a) screening for symptoms at either departure or arrival, b) sensitisation of arrivals to signs of illness, or c) a combination of both. We assume that sensitisation will result in a lower individual reproduction number for the traveller (e.g. by self-isolation and more rapid reporting which triggers contact tracing) and that syndromic screening reduces the number of infected travellers who can seed an outbreak. We then calculate the delay in reaching the outbreak threshold according to the number of infected travellers arriving each week, and the effectiveness of interventions a, b, and c, assuming the basic reproduction number to be gamma distributed with CIs ranging from 1.4 to 3.9. Because of the considerable uncertainty in the estimate we report no central estimates but rather 50% and 95% quantiles, focusing specifically on the lower bounds as a measure of likely minimal impact.
Results Summary We evaluated sensitisation effectiveness of 30, 50 and 70%, assuming either 1, 10, or 100 infected travellers per week. We found that early in the outbreak when only few infected travellers arrive, traveller sensitisation can delay a major outbreak in a previously unaffected region. For 50% effectiveness, and assuming 1 infected traveller per week, we find that in 75% of simulations the outbreak is delayed by at least 11 days (97.5% of simulations: at least 7 days). The possible delay decreases rapidly for more travellers, lower effectiveness of sensitisation, higher R0 or lower heterogeneity thereof. However, syndromic traveller screening at departure and/or arrival can further enhance impact. In combination with sensitisation, syndromic screening can delay an outbreak substantially longer. In 75% of simulations we find an outbreak delay of at least 111 days (97.5% of simulations: at least 23 days) for 1 infected traveller per week and at least 9 days (97.5% of simulations: at least 4 days) for 10 infected travellers per week.
Limitations include
We assume a constant rate of infected travellers. However, this may increase rapidly as the epidemic continues to spread exponentially in China and potentially elsewhere. There is currently little evidence for an exponential increase in infected travellers to Europe as airports in the highest risk regions have shut. If indeed infected traveller numbers were to increase exponentially numbers would increase from 1 to 10 and 100 per week within about 19 and 38 days respectively (assuming R=2.5 and serial interval of 7.5) and estimated delays would decrease accordingly.
The only estimate from the current outbreak for the variation between individuals in the number of secondary cases (k) is including large confidence intervals that span estimates for SARS and seasonal influenza. The estimated delay of an outbreak was highly sensitive to k.
We assume that syndromic surveillance at entry leads to immediate case isolation and hence no onward transmission. This is ignoring that during the flight the index case may have infected other travellers.
We assume that only sensitised travellers would pick up quickly on relevant symptoms and self-isolate and report to trigger contact tracing. Non sensitised travellers are assumed to not pay attention to early influenza-like symptoms during the winter season and hence only report with severe symptoms, i.e. when most of secondary cases have been infected and themselves have potentially further spread the virus. This may overestimate the estimated impact of sensitisation.
We don’t explicitly account for potential asymptomatic transmission. However, we implicitly do so as both the syndromic screening as well as the contact tracing work that infomed our estimates accounted for a small proportion of asymptomatic transmitters.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SF and SC are supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant number 208812/Z/17/Z). RME acknowledges an HDR UK Innovation Fellowship (Grant number MR/S003975/1). BQ was funded by the National Institute for Health Research (NIHR) (16/137/109) using UK aid from the UK Government to support global health research. PK was funded by the Bill & Melinda Gates Foundation (INV-003174). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the UK Department of Health and Social Care. The following authors were part of the Centre for Mathematical Modelling of Infectious Disease SARS-CoV-2 working group and contributed equally and appear in random order: Christopher I Jarvis, Yang Liu, Nikos I Bosse, Adam J Kucharski, W John Edmunds, Timothy W Russell, Sebastian Funk, Mark Jit, Hamish Gibbs, Sam Abbott, James D Munday, Amy Gimma, Carl AB Pearson, Charlie Diamond, Joel Hellewell. Each contributed in processing, cleaning and interpretation of data, interpreted findings, contributed to the manuscript, and approved the work for publication. We also like to thank John Edmunds, Graham Medley and Annelies Wilder-Smith for their helpful comments during the conception of this work.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The study contains no primary data